These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

859 related items for PubMed ID: 24919575

  • 1. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB.
    Clin Cancer Res; 2014 Aug 01; 20(15):4059-4074. PubMed ID: 24919575
    [Abstract] [Full Text] [Related]

  • 2. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
    Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Charles Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali G, Biswas R, Chaerkady R, Califano A, Pandey A, Guha U.
    Mol Cell Proteomics; 2017 May 01; 16(5):891-910. PubMed ID: 28331001
    [Abstract] [Full Text] [Related]

  • 3. T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
    Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K.
    Mol Cancer Ther; 2017 Nov 01; 16(11):2563-2571. PubMed ID: 28839001
    [Abstract] [Full Text] [Related]

  • 4. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, Soo RA, Christensen JG, Lee JH, Cho BC.
    Mol Cancer Ther; 2012 Oct 01; 11(10):2254-64. PubMed ID: 22891040
    [Abstract] [Full Text] [Related]

  • 5. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct 01; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 6. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
    Mol Cancer Ther; 2010 Jun 01; 9(6):1647-56. PubMed ID: 20530710
    [Abstract] [Full Text] [Related]

  • 7. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec 01; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 8. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun 01; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

  • 9. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.
    Oncotarget; 2015 Dec 29; 6(42):44274-88. PubMed ID: 26517520
    [Abstract] [Full Text] [Related]

  • 10. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    Wagener-Ryczek S, Heydt C, Süptitz J, Michels S, Falk M, Alidousty C, Fassunke J, Ihle MA, Tiemann M, Heukamp L, Wolf J, Büttner R, Merkelbach-Bruse S.
    BMC Cancer; 2020 May 12; 20(1):408. PubMed ID: 32397977
    [Abstract] [Full Text] [Related]

  • 11. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
    Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.
    Mol Cancer Ther; 2008 Apr 12; 7(4):874-9. PubMed ID: 18413800
    [Abstract] [Full Text] [Related]

  • 12. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
    Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Cancer Sci; 2010 Jan 12; 101(1):167-72. PubMed ID: 19804422
    [Abstract] [Full Text] [Related]

  • 13. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K.
    Thorac Cancer; 2020 Jan 12; 11(1):140-149. PubMed ID: 31758670
    [Abstract] [Full Text] [Related]

  • 14. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S, Im JH, Kim WK, Choi YJ, Lee JY, Kim SK, Kim SJ, Kwon SW, Kang KW.
    Oxid Med Cell Longev; 2021 Jan 12; 2021():5428364. PubMed ID: 34367462
    [Abstract] [Full Text] [Related]

  • 15. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
    Chung CT, Yeh KC, Lee CH, Chen YY, Ho PJ, Chang KY, Chen CH, Lai YK, Chen CT.
    Pharmacol Res; 2020 Nov 12; 161():105183. PubMed ID: 32896579
    [Abstract] [Full Text] [Related]

  • 16. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 17. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.
    Clin Cancer Res; 2009 May 15; 15(10):3484-94. PubMed ID: 19447865
    [Abstract] [Full Text] [Related]

  • 18. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T.
    Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326
    [Abstract] [Full Text] [Related]

  • 19. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
    Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S.
    Mol Cancer Ther; 2019 Aug 02; 18(8):1366-1373. PubMed ID: 31092564
    [Abstract] [Full Text] [Related]

  • 20. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.
    Cancer Sci; 2018 Oct 02; 109(10):3183-3196. PubMed ID: 30098066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.